Investors

  • 2021-03-31
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CHINA NMPA APPROVAL OF CLINICAL TRIAL APPLICATION TO EVALUATE TRODELVY® IN A PHASE 2 BASKET TRIAL FOR A VARIETY OF CANCERS WITH HIGH TROP-2 EXPRESSION
  • 2021-03-22
    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020
  • 2021-03-22
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON ACCEPTANCE OF NEW DRUG APPLICATION BY CHINA NMPA FOR XERAVA FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA
  • 2021-03-10
    DATE OF BOARD MEETING
  • 2021-03-05
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2021
  • 2021-03-01
    VOLUNTARY ANNOUNCEMENT SELECTION AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED
  • 2021-02-18
    VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF COMMERCIAL OFFICER
  • 2021-01-18
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON AMENDED AGREEMENT WITH SPERO THERAPEUTICS
  • 2021-01-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020
  • 2021-01-06
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC UROTHELIAL CANCER
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号